F2G
F2G develops novel therapeutics for rare, life-threatening fungal infections.
$100M Series B+ ·
Led by AMR Action Fund · Source: fundraisingfox.com
Funding history ↓Signals
About F2G
The company creates new antifungal drugs, including olorofim, which is part of a new class of antifungal drugs called orotomides. F2G aims to provide more treatment options for patients fighting these infections.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series B+ | $100M | fundraisingfox.com |
Timeline
- Website created
Founders and team
DD
David Denning FounderCW
Christopher Wright Non Executive DirectorRP
Raj Parekh Non Executive DirectorIN
Ian Nicholson Chief Executive OfficerJA
Janelle Anderson Chief Business OfficerJR
John Rex Chief Medical OfficerMB
Mike Birch Chief Operating OfficerRS
Ralf Schmid Chief Financial OfficerTK
Tony Kennedy Chief Scientific and Development Officer
Investors
AAdvent Life Sciences
AAMR Action Fundlead investor
BBrace Pharma
CCowen Healthcare Investments
EEuropean Investment Bank Group
FForbion Capital Partners
IIntermediate Capital Grouplead investor
MMorningside
NNovo Ventures
SSofinnova Partners
Companies like F2G
BBiossil$153M Seed · Sep 2026
OOna Therapeutics$86.6M Series B+ · Oct 2026
NNoema PharmaSeries B+ · Nov 2025
CCayuga BiotechFFountain Life$18M Series B+ · Aug 2025
CCentauri Therapeutics$32.3M Series A · Feb 2026
Other companies backed by AMR Action Fund
VVedanta Biosciences$60M Series B+ · Aug 2026
PPeptilogics$78M Series B+ · Oct 2025
AAdaptive Phage Therapeutics$24M Series B+ · Jun 2023
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/f2g (get a free API key).